Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multi-dose DDO-3055 in Anemia of Non-dialysis CKD
NCT04470063Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DDO-3055 in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Hengrui. Primary endpoint: Incidence and severity of adverse events up to 37 days. Status: unknown.
02
Drugs
DDO-3055
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04470063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04470063.